[ad_1]
A cure for cancer within a year? This is what promises a start-up ] based on ] Israel states Jerusalem Post . "We believe that we can offer comprehensive cancer treatment in one year ," says Dan Aridor., Chairman of the board of directors of Accelerated Evolution Biotechnologies (AEBI) [19659003] According to Aridor, the cure compared to the treatments available today. He quotes, for example, "no or almost no side effects at a cost well below most available treatments".
The treatment was called a multi-target toxin, which uses a technology called SoAP, which is part of phage display techniques, in which a virus infecting a bacterium can be used to develop new proteins.
+ What is the "virtual tumor", a new way of studying cancer
The AEBI technique allows for similar work, but uses peptides. According to Ilan Morad, founder and CEO of the start-up, peptides are cheaper, simpler to produce and control
According to him, cancer treatment techniques fail because they target specific targets. MuTaTo does the exact opposite, using a combination of several peptides that attack multiple cancer cells at the same time. According to Morad, the use of at least three peptides in the same structure "ensures that the treatment will not be affected by mutations". According to him, it is important to completely cancel the cancer so that no new mutation occurs.
+ 4 futuristic inventions likely to arrive in 2019 and modify our state of health
In Jerusalem Post he compares the solutions of his start to the change in the treatment of AIDS with the arrival badtail. "We used to give various drugs [aos pacientes] but one at a time," he explains. "During the treatment, the virus was mutated and AIDS attacked again, the disease stopped only when the patients started taking the badtail." Today, the patients carry the HIV virus, but are not sick. Unlike AIDS, however, with MuTaTo, cancer cells would be killed and no medication needed for the rest of their lives.
According to Morad, experiments on mice bearing human cancer cells have been successful. The startup should now begin clinical trials, which should end in a few years, providing specific treatment for cancer cases. "Our results are consistent and repeated," says Aridor.
Source link
